These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17927924)

  • 1. Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
    Conlin AK; Seidman AD
    J Natl Compr Canc Netw; 2007 Sep; 5(8):668-72. PubMed ID: 17927924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.
    Cianfrocca M; Gradishar WJ
    J Natl Compr Canc Netw; 2007 Sep; 5(8):673-5. PubMed ID: 17927925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Köstler WJ; Brodowicz T; Zielinski CC;
    J Natl Cancer Inst; 2010 Feb; 102(3):207; author reply 207-8. PubMed ID: 20054016
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy.
    Chlebowski RT; Irwin LE; Pugh RP; Sadoff L; Hestorff R; Wiener JM; Bateman JR
    Cancer Res; 1979 Nov; 39(11):4503-6. PubMed ID: 387216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Chlebowski RT
    J Natl Cancer Inst; 2010 Jan; 102(2):137. PubMed ID: 20019336
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.
    Wilcken N; Dear R
    Eur J Cancer; 2008 Oct; 44(15):2218-25. PubMed ID: 18722111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
    Smalley RV; Murphy S; Huguley CM; Bartolucci AA
    Cancer Res; 1976 Nov; 36(11 Pt 1):3911-6. PubMed ID: 975039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination versus sequential single-agent therapy in metastatic breast cancer.
    Miles D; von Minckwitz G; Seidman AD
    Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single agent versus combination chemotherapy for metastatic breast cancer.
    Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
    Ocaña A; Hortobagyi GN; Esteva FJ
    Clin Breast Cancer; 2006 Feb; 6(6):495-504. PubMed ID: 16595032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
    Crown J
    Lancet; 2003 Aug; 362(9385):677-8. PubMed ID: 12957087
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line Herceptin monotherapy in metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
    Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" result.
    Chlebowski RT; Weiner JM; Ryden VM; Bateman JR
    Control Clin Trials; 1981 Jun; 2(2):123-32. PubMed ID: 7273791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience.
    Köstler WJ; Steger GG; Krainer M; Kornek GV; Locker GJ; Brodowicz T; Marosi C; Singer CF; Hudelist G; Rabitsch W; Wiltschke C; Zielinski CC
    Anticancer Drugs; 2005 Feb; 16(2):185-90. PubMed ID: 15655416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.